- Karpe, Hodson and Christodoulides Group: Metabolic Research Group Research Group
- Tomlinson Group: Metabolism and Steroid Hormone Biology Research Group
BA MBchB MRCP
Wellcome Trust Clinical Research Fellow & DPhil Student
My current research focuses on the link between obstructive sleep apnoea and diabetes. Obstructive sleep apnoea (OSA) is characterised by intermittent nocturnal hypoxia (IH) and is tightly associated with diabetes conveying increased cardiovascular risk. The adverse metabolic phenotype observed in OSA is similar to that seen in states of glucocorticoid (GC) excess (Cushing's syndrome) including central adiposity, proximal myopathy, hypertension, hyperlipidaemia, insulin resistance, T2DM and hepatic steatosis. My work looks to test the hypothesis that the metabolic phenotype seen in OSA is mediated by increased glucocorticoid signaling. My main expertise is in running human physiological studies to address key metabolic questions. The techniques I use in these studies typically include hyperinsulinaemic clamps to assess insulin resistance, stable isotope tracers to study lipid and carbohydrate metabolism adipose tissue biopsy, adipose microdialysis to assess adipose tissue function. The in vitro methods I employ are GCMS of lipid metabolites/urinary steroids, adipose biopsy processing for gene expression and western blotting, ELISAs, Fluorescence assays, and high throughput metabolic assays.
Advanced non-alcoholic fatty liver disease and adipose tissue fibrosis in patients with Alström syndrome.
Gathercole LL. et al, (2016), Liver Int, 36, 1704 - 1712
Non-alcoholic fatty liver disease and diabetes.
Hazlehurst JM. et al, (2016), Metabolism, 65, 1096 - 1108
Response to the Letter: "Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man".
Hazlehurst JM. and Tomlinson JW., (2016), The Journal of clinical endocrinology and metabolism, 101, L48 - L49
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Armstrong MJ. et al, (2016), Lancet, 387, 679 - 690
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
Armstrong MJ. et al, (2016), J Hepatol, 64, 399 - 408